COM701

DRUG2 trials

Sponsors

Compugen Ltd

Conditions

Advanced CancerBreast CancerColo-rectal CancerEndometrial CancerLung CancerLung NeoplasmNeoplasm MalignantOvarian Cancer

Phase 1

COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.

CompletedNCT03667716

Compugen LtdAdvanced Cancer, Breast Cancer, Colo-rectal Cancer +7

Start: 2018-09-06End: 2024-01-30Updated: 2025-01-17

A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

RecruitingNCT06888921

Compugen LtdOvarian Cancer, Ovarian Cancer Recurrent

Start: 2025-07-21End: 2027-03-01Target: 60Updated: 2026-04-01

Related Papers

Abstract LB237: PVRL2 suppresses antitumor immune responses through PVRIG- and TIGIT-independent pathways

Cancer Research2024-04-05

29 Immune modulation and baseline biomarker correlation with clinical benefit following treatment with COM701+nivolumab+/-BMS-986207 in patients with platinum resistant ovarian cancer

Regular and Young Investigator Award Abstracts2023-10-31

640 The combination of COM701 + nivolumab demonstrates preliminary antitumor activity in patients with metastatic breast cancer

Regular and Young Investigator Award Abstracts2023-10-31

659 COM701 plus nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastases

Regular and Young Investigator Award Abstracts2022-11-014 citations

504 PVRIG, a novel T cell checkpoint, is preferentially expressed in TLS on stem-like memory T cells, potentially inhibiting their expansion

Regular and Young Investigator Award Abstracts2022-11-011 citations

Dostarlimab: A Review.

2022-07-2639 citations

478 COM701 in combination with BMS-986207 (anti-TIGIT antibody) and nivolumab – preliminary results of safety, tolerability and pharmacokinetics in patients with advanced solid tumors (NCT04570839)

Regular and Young Investigator Award Abstracts2021-11-018 citations

252 Novel DNAM-1 axis member, PVRIG, is potentially a dominant checkpoint involved in stem-like memory T cells – dendritic cell interaction

Regular and Young Investigator Award Abstracts2021-11-012 citations

COM701 with or without nivolumab: Results of an ongoing phase 1 study of safety, tolerability and preliminary antitumor activity in patients with advanced solid malignancies (NCT03667716).

Journal of Clinical Oncology2021-05-2015 citations

A phase I study evaluating COM701 monotherapy and in combination with nivolumab in patients with advanced solid malignancies.

Journal of Clinical Oncology2020-02-044 citations

390 COM701 (a novel immune checkpoint inhibitor) in patients with advanced solid tumors

2019-09-01

Abstract CT168: Phase I study of COM701 (a novel checkpoint inhibitor of PVRIG) in patients with advanced solid tumors

Cancer Research2019-07-012 citations

Abstract CT168: Phase I study of COM701 (a novel checkpoint inhibitor of PVRIG) in patients with advanced solid tumors

Clinical Trials2019-07-011 citations

A phase I study evaluating COM701 in patients with advanced solid tumors.

Journal of Clinical Oncology2019-05-20

A phase I study evaluating COM701 in patients with advanced solid tumors.

Journal of Clinical Oncology2019-03-10